Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities

Connective tissue disease associated interstitial lung disease (CTD-ILD) remains the poor cousin, with regards to specific disease modifying therapies. CTD in general and rheumatoid arthritis (RA) in particular has seen a surge of investment by industry and the provision of a range of therapies that significantly improve the quality of life for these patients.¹ More recently, two novel anti-fibrotic therapies for idiopathic pulmonary fibrosis (IPF) have been shown to significantly modify disease and improve survival.^2–4 Yet, for pulmonary fibrosis arising in those with CTD, there remains a desperate need to identify effective therapies.

from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2uRUEfm